CNS demyelination associated with immune dysregulation and a novel CTLA-4 variant
- PMID: 34097529
- PMCID: PMC8358566
- DOI: 10.1177/1352458520963896
CNS demyelination associated with immune dysregulation and a novel CTLA-4 variant
Abstract
Background: The cytotoxic T-lymphocyte antigen-4 (CTLA-4) pathway acts as a negative immune regulator of T-cell activation and promotes self-tolerance.
Case: We report the first case of biopsy-proven central nervous system inflammatory demyelination in the context of primary immunodeficiency and a novel CTLA-4 variant.
Conclusion: This case has significant implications for the development of novel treatments for autoimmune conditions including multiple sclerosis and further emphasises the need for caution with clinical use of CTLA-4 immune checkpoint inhibitors in those with a history of inflammatory demyelination.
Keywords: CTLA-4; demyelination.
Conflict of interest statement
Figures

References
-
- Cooper N, Te Water Naude J, Connor PP.Neuromyelitis optica complicating autoimmune lymphoproliferative syndrome in a 4-year-old girl. Br J Haematol 2011; 152(3): 247. - PubMed
-
- Engelhardt JJ, Sullivan TJ, Allison JP.CTLA-4 overexpression inhibits T cell responses through a CD28-B7-dependent mechanism. J Immunol 2006; 177: 1052–1061. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical